Drugs / MAX-10181
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05196360 | Aug 2021 → Jan 2023 | cancer | Maxinovel Pty., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04122339 | Feb 2020 → Oct 2022 | neoplasm | Maxinovel Pty., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAX-10181 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04122339 ↗ |
| Modality | Small molecule | — CHEMBL5095188 ↗ |
| Route | Oral | “MAX-10181 Given Orally to Patients With Advanced Solid Tumor” NCT04122339 ↗ |